Browsing Tag
Shingrix
10 posts
GSK specialty medicines sales rise 15% as £328m restructuring charge weakens reported profit
GSK reported £8.89 billion in third-quarter sales as specialty medicines expanded strongly across HIV, respiratory diseases and oncology. However, vaccines remained weak and a £328 million restructuring charge contributed to lower statutory earnings, while management maintained its 2026 and 2031 growth targets.
GSK Q2 2026 core operating profit rises 7% on specialty medicines strength
GSK Q2 core operating profit rose 7% to £2.8bn, but a £1.3bn camlipixant hit and 2028-2030 dolutegravir cliff frame the £40bn 2031 sales delivery test.
GSK trades near 2,027p as Q1 core EPS rises 9%, full-year 2026 guidance reaffirmed
GSK beat the top line and held guidance, but the harder question is whether Specialty Medicines can keep outrunning the Vaccines and General Medicines drag.
GSK FY2025 results show momentum in HIV and oncology while vaccines and general medicines face pressure
GSK’s FY2025 core EPS grew 12 percent with strong Specialty Medicines performance. Find out how the company is planning to sustain momentum in 2026.
Positive CHMP opinion sets stage for GSK’s ready-to-use Shingrix syringe approval in Europe
GSK receives CHMP green light for Shingrix prefilled syringe. Learn how this vaccine format could simplify shingles protection across Europe.
GSK’s Shingrix wins China approval for adults 18+ — Can this vaccine expansion reignite its global growth story?
Find out how GSK’s Shingrix approval in China for adults aged 18+ could reshape its vaccine business and investor confidence. #GSK #Shingrix
GSK India delivers 32% profit surge—Zejula and Jemperli launches set to transform cancer care
GSK India reports 32% PAT growth in FY25; read how oncology launches and vaccine growth are shaping the company’s future outlook.
GSK reveals significant Shingrix vaccine efficacy in ZOSTER-049 trial
GSK plc announced the results of the ZOSTER-049 phase III long-term follow-up trial, showcasing that the Shingrix (Recombinant…
GSK seeks to extend shingles vaccine Shingrix to younger at-risk adults in China
GSK plc (LSE/NYSE: GSK) has reached a pivotal milestone in the prevention of shingles (herpes zoster) in China,…
China’s shingles vaccine landscape revolutionized as GSK partners with Zhifei
Global pharmaceutical titan GSK plc is teaming up with Chongqing Zhifei Biological Products, Ltd. (Zhifei) – China’s leading…